Conclusion of non-exclusive pharmaceutical rebate agreements pursuant to § 130a para. 8 SGB V by means of an open-house model for the active ingredient flecainide (ATC code according to WHO: C01BC04)
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Flecainid (ATC-Code nach WHO: C01BC04)
Germany · Erfurt
Contract
BuyerAOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen
TypeSupplies
Estimated valuevalue not published
Published8 October 2025
CategoryMedical equipment & pharma · CPV 33600000
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Hexal AG · Holzkirchen | 45 | 2013–2024 |
| Aliud Pharma GmbH · Laichingen | 41 | 2013–2021 |
| ratiopharm GmbH | 37 | 2016–2024 |
| betapharm Arzneimittel GmbH · Augsburg | 35 | 2013–2021 |
| axicorp Pharma B.V. · EC Den Haag | 30 | 2016–2021 |
From 13.7M documented awards · regular winners know this buyer's requirements — that is your competition.
How often this buyer tenders this
2019282
2020224
2021274
2022178
2023247
2024285
2025539
2026219
Who knows the rhythm prepares instead of reacting.
529
days until the deadline — Monday 31 January at 00:00
How to bid
Read the full notice — Original + documents
Goes directly to this tender on TED — Tenders Electronic Daily. The full specification and all annexes are there.
Tenders like this, every morning at 7:30 in your inbox.
Start free →